WHAT WE OFFER
A Revolution has come to Diabetes.
Note the use of the past tense. It’s not something that’s going to happen. It’s here now.
Developed by a physicist and not a physician, it’s Afrezza.
Like all revolutions, this one has toppled an established order. Historically, blood sugar control was a battle between being too high or too low, hyperglycemia or hypoglycemia. Historically, as one lowered HbA1c, one increased the hypoglycemic risk. Historically, good control meant pain: injections and finger sticks.
All that’s been swept aside. It’s history. For too long, diabetes has been a curse for patients and a burden for their loved ones.
It stops NOW. No more.
Through the use of Afrezza, Vdex has one simple aim: to ENABLE DIABETICS TO LIVE A NORMAL OR NEARLY NORMAL LIFE.
A disease unlike most other medical conditions, diabetes is a chronic condition with devastating long-term consequences. It requires hour-by-hour attention to avoid equally devastating short-term consequences. Patients need regular care and monitoring for life.
Through our "Real Time Diabetes Management" model, diabetics have far better control of blood glucose levels and reduced hypoglycemia as compared to the current, best therapies available today.
Revolutions are usually borne of the people. People with diabetes died 10 – 15 years sooner than non-diabetics. People with diabetes suffered with monstrous complications. People with diabetes were notoriously non-compliant. People are now free to live a new, fuller life with diabetes, one where they’re in control.
Revolutions face long odds of success and only seem obvious in retrospect. But you don't have to wait for the revolution, you can join it now.
We have distilled our belief for the future of this disease to the following:
Afrezza first, Afrezza instead, Afrezza always.
A Brief insight into Vdex General Patient Observation
In the course of Vdex’ treatment we have followed 30 randomly selected patients of different ethnicities, genders, ages (including juveniles) and different types (both 1 & 2), as well as different stages of disease (early and late), mildly controlled to severely uncontrolled. We have yet to see a single case of severe hypoglycemia. In fact, we saw less hypoglycemia overall as patients’ blood glucose levels flattened and stabilized. We have treated both insulin naïve and insulin dependent patients, patients with reasonable control (A1c of 6.8) and severely uncontrolled (A1c of 14). We have treated patients at low doses (4 units at dinner only) and high doses (30 units at three meals for 100 units in a day).
We strongly recommended the use of continuous glucose monitors (CGM) initially in all patients, but not all opted to use the devices. From their CGM readings we saw a very consistent pattern. Patients’ blood glucose levels flattened, the highs weren’t as high and the lows weren’t as low. In other words, we saw lowered HbA1c readings AND less hypoglycemia AT THE SAME TIME.
Figures 1. – 3. below serve to make the point well. The first illustrates typical, non-diabetic glucose levels as measured on a CGM. The second shows CGM tracings for typical insulin-dependent diabetic blood sugar levels, and the third shows what can be achieved on Afrezza. While not all patients can achieve the level of control reflected in the third graph, ALL AFREZZA USERS THAT WE STUDIED SHOWED FLATTENED CURVES such as is illustrated here.